Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.68
NAS:ALKS's Cash-to-Debt is ranked lower than
75% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:ALKS: 1.68 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ALKS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 1.54 Max: No Debt
Current: 1.68
Equity-to-Asset 0.69
NAS:ALKS's Equity-to-Asset is ranked higher than
53% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:ALKS: 0.69 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ALKS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.15  Med: 0.66 Max: 0.97
Current: 0.69
-0.15
0.97
Piotroski F-Score: 4
Altman Z-Score: 8.55
Beneish M-Score: -2.82
WACC vs ROIC
14.00%
-19.17%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -24.87
NAS:ALKS's Operating Margin % is ranked higher than
62% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:ALKS: -24.87 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ALKS' s Operating Margin % Range Over the Past 10 Years
Min: -35.7  Med: -18.36 Max: 41.29
Current: -24.87
-35.7
41.29
Net Margin % -24.33
NAS:ALKS's Net Margin % is ranked higher than
62% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:ALKS: -24.33 )
Ranked among companies with meaningful Net Margin % only.
NAS:ALKS' s Net Margin % Range Over the Past 10 Years
Min: -36.15  Med: -13.55 Max: 69.37
Current: -24.33
-36.15
69.37
ROE % -16.09
NAS:ALKS's ROE % is ranked higher than
65% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:ALKS: -16.09 )
Ranked among companies with meaningful ROE % only.
NAS:ALKS' s ROE % Range Over the Past 10 Years
Min: -18.25  Med: -5.96 Max: 65.64
Current: -16.09
-18.25
65.64
ROA % -11.27
NAS:ALKS's ROA % is ranked higher than
66% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:ALKS: -11.27 )
Ranked among companies with meaningful ROA % only.
NAS:ALKS' s ROA % Range Over the Past 10 Years
Min: -12.04  Med: -4.55 Max: 27.26
Current: -11.27
-12.04
27.26
ROC (Joel Greenblatt) % -55.54
NAS:ALKS's ROC (Joel Greenblatt) % is ranked higher than
66% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:ALKS: -55.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ALKS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -61.03  Med: -16.97 Max: 131.93
Current: -55.54
-61.03
131.93
3-Year Revenue Growth Rate 5.50
NAS:ALKS's 3-Year Revenue Growth Rate is ranked higher than
53% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:ALKS: 5.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ALKS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -20.2  Med: 9.9 Max: 69.6
Current: 5.5
-20.2
69.6
GuruFocus has detected 1 Warning Sign with Alkermes PLC $NAS:ALKS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ALKS's 30-Y Financials

Financials (Next Earnings Date: 2017-11-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ALKS Guru Trades in Q3 2016

George Soros 4,600 sh (New)
PRIMECAP Management 3,153,560 sh (+25.87%)
Ken Fisher 129,607 sh (+5.29%)
Jeff Auxier 26,751 sh (unchged)
Vanguard Health Care Fund 8,603,676 sh (unchged)
Murray Stahl 25,000 sh (unchged)
Pioneer Investments 155,087 sh (-37.76%)
» More
Q4 2016

ALKS Guru Trades in Q4 2016

Steven Cohen 84,400 sh (New)
PRIMECAP Management 6,376,270 sh (+102.19%)
George Soros 7,200 sh (+56.52%)
Vanguard Health Care Fund 8,660,076 sh (+0.66%)
Jeff Auxier 26,751 sh (unchged)
Murray Stahl 25,000 sh (unchged)
Ken Fisher 118,407 sh (-8.64%)
Pioneer Investments 103,137 sh (-33.50%)
» More
Q1 2017

ALKS Guru Trades in Q1 2017

Jim Simons 124,886 sh (New)
Joel Greenblatt 51,566 sh (New)
Steven Cohen 250,200 sh (+196.45%)
PRIMECAP Management 7,856,543 sh (+23.22%)
Vanguard Health Care Fund 8,694,176 sh (+0.39%)
Murray Stahl 25,000 sh (unchged)
George Soros Sold Out
Pioneer Investments Sold Out
Jeff Auxier 26,651 sh (-0.37%)
Ken Fisher 110,407 sh (-6.76%)
» More
Q2 2017

ALKS Guru Trades in Q2 2017

PRIMECAP Management 9,869,291 sh (+25.62%)
Vanguard Health Care Fund 8,694,176 sh (unchged)
Jeff Auxier 26,651 sh (unchged)
Joel Greenblatt Sold Out
Jim Simons Sold Out
Ken Fisher 110,212 sh (-0.18%)
Murray Stahl 22,000 sh (-12.00%)
Steven Cohen 96,000 sh (-61.63%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ALKS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-06-30 Reduce -0.18%$55.9 - $61.66 $ 50.90-12%110,212
Joel Greenblatt 2017-06-30 Sold Out 0.04%$55.9 - $61.66 $ 50.90-12%0
Vanguard Health Care Fund 2017-03-31 Add 0.39%$52.26 - $61.16 $ 50.90-10%8,694,176
Ken Fisher 2017-03-31 Reduce -6.76%$52.26 - $61.16 $ 50.90-10%110,407
Joel Greenblatt 2017-03-31 New Buy0.04%$52.26 - $61.16 $ 50.90-10%51,566
George Soros 2017-03-31 Sold Out 0.01%$52.26 - $61.16 $ 50.90-10%0
Vanguard Health Care Fund 2016-12-31 Add 0.66%0.01%$42.3 - $59.5 $ 50.90-5%8,660,076
Ken Fisher 2016-12-31 Reduce -8.64%$42.3 - $59.5 $ 50.90-5%118,407
George Soros 2016-12-31 Add 56.52%$42.3 - $59.5 $ 50.90-5%7,200
Ken Fisher 2016-09-30 Add 5.29%$43.77 - $51.78 $ 50.907%129,607
George Soros 2016-09-30 New Buy0.01%$43.77 - $51.78 $ 50.907%4,600
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:JAZZ, NAS:PRTA, NAS:AMRN, NAS:AVDL, NAS:NVET, LSE:SHP » details
Traded in other countries:8AK.Germany,
Headquarter Location:Ireland
Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.

Alkermes is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Top Ranked Articles about Alkermes PLC

What Markets Are Really Looking for in Alkermes' Schizophrenia Drug The fate of the drug rests on the results of a phase 3 study
On June 30, Alkermes PLC (NASDAQ:ALKS) released data from a phase 3 study of one of its lead development assets, a drug called ALKS 3831. This study is the first of two phase 3 investigations designed to underpin an application with the U.S. Food and Drug Administration seeking regulatory approval for this drug in a target indication of schizophrenia. If approved, there is a large potential market waiting for the drug when it hits shelves. Ahead of any approval, however, there are a number of points against which it must perform. Read more...
Who Is Winning the Fight Against Opioid Abuse? A recent survey found approximately 23.5 million Americans are addicted to drugs and alcohol
The extent of the opioid epidemic in the U.S. is so pervasive that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) National Survey on Drug Use and Health estimated that around 23.5 million Americans, aged 12 or older, are addicted to drugs and alcohol. Read more...
Naltrexone Showing More Potential in Drug Addiction Treatment Market Teva Pharmaceuticals and Alkermes produce 2 main forms of treatment
In the on-going debate of which drug addiction treatment is more effective, naltrexone is showing more potential than buprenorphine, according to the latest study by researchers from Columbia University. Read more...
BioCorRx Receives New Funding for Opioid Drug 21st Century Cures Act promises $1 billion in research funding
The signing last month of the 21st Century Cures Act into law by President Barack Obama signals a major revamp in the treatment of opioid addiction because of the promise of $1 billion in research funding, as well as a system to hasten approval of drugs and medicine devices by the Food and Drug Administration. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 5000.00
ALKS's Forward PE Ratio is ranked lower than
99.99% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. ALKS: 5000.00 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 6.51
ALKS's PB Ratio is ranked lower than
75% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. ALKS: 6.51 )
Ranked among companies with meaningful PB Ratio only.
ALKS' s PB Ratio Range Over the Past 10 Years
Min: 1.66  Med: 4.25 Max: 10.58
Current: 6.51
1.66
10.58
PS Ratio 9.65
ALKS's PS Ratio is ranked higher than
52% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. ALKS: 9.65 )
Ranked among companies with meaningful PS Ratio only.
ALKS' s PS Ratio Range Over the Past 10 Years
Min: 2.19  Med: 7.1 Max: 18.85
Current: 9.65
2.19
18.85
EV-to-EBIT -39.33
ALKS's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. ALKS: -39.33 )
Ranked among companies with meaningful EV-to-EBIT only.
ALKS' s EV-to-EBIT Range Over the Past 10 Years
Min: -17501.7  Med: -23.3 Max: 436.6
Current: -39.33
-17501.7
436.6
EV-to-EBITDA -78.46
ALKS's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. ALKS: -78.46 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALKS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1362.6  Med: 5 Max: 262.1
Current: -78.46
-1362.6
262.1
Current Ratio 3.54
ALKS's Current Ratio is ranked lower than
54% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ALKS: 3.54 )
Ranked among companies with meaningful Current Ratio only.
ALKS' s Current Ratio Range Over the Past 10 Years
Min: 2.01  Med: 6.2 Max: 35.69
Current: 3.54
2.01
35.69
Quick Ratio 3.20
ALKS's Quick Ratio is ranked lower than
53% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. ALKS: 3.20 )
Ranked among companies with meaningful Quick Ratio only.
ALKS' s Quick Ratio Range Over the Past 10 Years
Min: 1.95  Med: 5.94 Max: 35.69
Current: 3.2
1.95
35.69
Days Inventory 149.33
ALKS's Days Inventory is ranked lower than
52% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. ALKS: 149.33 )
Ranked among companies with meaningful Days Inventory only.
ALKS' s Days Inventory Range Over the Past 10 Years
Min: 86.09  Med: 128.98 Max: 166.33
Current: 149.33
86.09
166.33
Days Sales Outstanding 90.62
ALKS's Days Sales Outstanding is ranked lower than
61% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. ALKS: 90.62 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALKS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.46  Med: 82.14 Max: 93.54
Current: 90.62
27.46
93.54
Days Payable 132.52
ALKS's Days Payable is ranked higher than
77% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. ALKS: 132.52 )
Ranked among companies with meaningful Days Payable only.
ALKS' s Days Payable Range Over the Past 10 Years
Min: 39.15  Med: 65.98 Max: 127.84
Current: 132.52
39.15
127.84

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.50
ALKS's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. ALKS: -4.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALKS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.1  Med: -10.2 Max: 2.1
Current: -4.5
-16.1
2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 29.42
ALKS's Price-to-Net-Current-Asset-Value is ranked lower than
90% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. ALKS: 29.42 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALKS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.18  Med: 7.3 Max: 343
Current: 29.42
2.18
343
Price-to-Tangible-Book 9.52
ALKS's Price-to-Tangible-Book is ranked lower than
78% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ALKS: 9.52 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALKS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.24  Med: 7.7 Max: 365.22
Current: 9.52
1.24
365.22
Price-to-Intrinsic-Value-Projected-FCF 9.86
ALKS's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
78% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. ALKS: 9.86 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALKS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2  Med: 4.15 Max: 20.95
Current: 9.86
2
20.95
Price-to-Median-PS-Value 1.36
ALKS's Price-to-Median-PS-Value is ranked lower than
77% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ALKS: 1.36 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALKS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 1.57 Max: 14.45
Current: 1.36
0.38
14.45
Earnings Yield (Greenblatt) % -2.54
ALKS's Earnings Yield (Greenblatt) % is ranked higher than
67% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. ALKS: -2.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALKS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -6  Med: -0.6 Max: 53.4
Current: -2.54
-6
53.4

More Statistics

Revenue (TTM) (Mil) $804.37
EPS (TTM) $ -1.28
Beta2.27
Short Percentage of Float9.14%
52-Week Range $41.93 - 63.40
Shares Outstanding (Mil)153.66

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 909 1,089 1,365
EPS ($) 0.01 0.46 1.70
EPS without NRI ($) 0.01 0.46 1.70
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:ALKS

Headlines

Articles On GuruFocus.com
What Markets Are Really Looking for in Alkermes' Schizophrenia Drug Jul 05 2017 
7 Outperforming Stocks With Rising Prices Jun 27 2017 
Stocks That Are Beating the Market Apr 12 2017 
Drug Addiction Treatment Should Start in Emergency Room Apr 04 2017 
Who Is Winning the Fight Against Opioid Abuse? Feb 27 2017 
Naltrexone Showing More Potential in Drug Addiction Treatment Market Feb 05 2017 
BioCorRx Receives New Funding for Opioid Drug Jan 22 2017 
US Prisons Experiment With Addiction Treatment for Inmates Nov 29 2016 
AvalonBay Communities, Equinix, Jarden, Alkermes Approach 52-Week Highs Jan 04 2016 
Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 

More From Other Websites
See what the IHS Markit Score report has to say about Alkermes PLC. Aug 16 2017
ETFs with exposure to Alkermes Plc : August 14, 2017 Aug 14 2017
Edited Transcript of ALKS earnings conference call or presentation 27-Jul-17 12:30pm GMT Aug 13 2017
IHS Markit Score downgrades Alkermes PLC to 63 out of 100, ranking positively in only one out of... Aug 11 2017
IHS Markit Score upgrades Alkermes PLC to 71 out of 100, despite ranking positively in only one IHS... Aug 10 2017
Alkermes Plc :ALKS-US: Earnings Analysis: Q2, 2017 By the Numbers : July 31, 2017 Jul 31 2017
3 Biotech Stocks for Enterprising Investors Jul 29 2017
Alkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat Jul 28 2017
Alkermes Continues to Execute Jul 28 2017
Alkermes reports 2Q loss Jul 28 2017
Alkermes plc Reports Second Quarter 2017 Financial Results Jul 27 2017
ETFs with exposure to Alkermes Plc : July 24, 2017 Jul 24 2017
Alkermes to Host Conference Call to Discuss Second Quarter 2017 Financial Results Jul 20 2017
Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : July 19, 2017 Jul 19 2017
Attention Biotech Investors: Keep Your Date With July PDUFA Action-Days Jul 05 2017
Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More Jul 05 2017
Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : July 4, 2017 Jul 04 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}